The first global approval  of sarilumab  in Canada has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.

Sarilumab (Kevzara™), developed by Sanofi and Regeneron Pharmaceuticals, was also approved in  the US (May 2017)[1] and Europe (June 2017)[2] for use in combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to – or who are intolerant to – one or more disease modifying anti-rheumatic drugs (DMARDs), such as MTX. The agent may also be used alone in patients with intolerance to, or are contraindicated for methotrexate.

For further information related to the first approval of sarilumab please visit Drugs or to learn more about the overall development of sarilumab across all indications visit AdisInsight.

Image credit:  Ivelin Radkov / Fotolia

One thought on “Sarilumab (Kevzara™): Follow up Approvals in US and Europe

Leave a Reply